Disease

Stowers Institute for Medical Research appoints new Assistant Investigator

Retrieved on: 
Tuesday, April 30, 2024
Science, Cancer, Investigator, Bangladesh Technical Education Board, Protein, Cell, Health, Disease, Heart, Research, NYU, Life, Medical research, Assistant, Biology, Kostov, Ribosome, Engineering, Knowledge, MIT

KANSAS CITY, Mo., April 30, 2024 /PRNewswire/ -- The Stowers Institute for Medical Research announces the appointment of Kamena Kostova, Ph.D., as its newest Principal Investigator. Kostova, an accomplished cellular and molecular biologist, will join the Institute as an Assistant Investigator in Fall 2024.

Key Points: 
  • Kamena Kostova, Ph.D., a molecular biologist from Carnegie Science, will open her lab at the Stowers Institute in Fall 2024.
  • KANSAS CITY, Mo., April 30, 2024 /PRNewswire/ -- The Stowers Institute for Medical Research announces the appointment of Kamena Kostova, Ph.D. , as its newest Principal Investigator.
  • Kostova, an accomplished cellular and molecular biologist, will join the Institute as an Assistant Investigator in Fall 2024.
  • "We are delighted to welcome and count Dr. Kamena Kostova as our newest Principal Investigator at the Stowers Institute," said Alejandro Sánchez Alvarado, Ph.D. , President and Chief Scientific Officer of the Stowers Institute.

Accelerating Clinical Development through Design, Diversity & Digitalization in Oncology and Beyond, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 30, 2024
DEI, EMBA, ROI, Ecosystem, Innovation, MD, Artificial intelligence, Intelligence, Disease, Digital health, Patient, Legislation, Eye, Machine learning, Drug development

TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this dynamic panel-type webinar, the expert speakers will explore how to speed drug development and improve return on investment (ROI) by adopting a "3-D" approach to trials focusing on design, diversity and digitalization.

Key Points: 
  • In this free webinar, attendees will gain insights into novel approaches to keep clinical development on track.
  • TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this dynamic panel-type webinar, the expert speakers will explore how to speed drug development and improve return on investment (ROI) by adopting a "3-D" approach to trials focusing on design, diversity and digitalization.
  • Therefore, attendance is recommended across all therapeutic areas, ranging from cardiovascular to neuroscience to rare disease and, in fact, any enrollment-challenged indications.
  • Register for this webinar today to gain insights into innovative approaches to keeping clinical development on track to meet timelines and other KPIs.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Tuesday, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Tuesday, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

ELIAS Animal Health Expands Manufacturing Capacity Ahead of Product Approval and Pipeline Expansion

Retrieved on: 
Tuesday, April 30, 2024
Cancer, USDA, Autotransplantation, Disease, Therapy, CFR, Patient, Osteosarcoma, Dog, Standard of care, Pharmaceutical industry

OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health , a leading companion animal cancer therapeutics company, is expanding its manufacturing capacity in a larger facility located in Lenexa, Kansas as it prepares for the commercial product launch of the ELIAS Cancer Immunotherapy (ECI®) later this year.

Key Points: 
  • OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health , a leading companion animal cancer therapeutics company, is expanding its manufacturing capacity in a larger facility located in Lenexa, Kansas as it prepares for the commercial product launch of the ELIAS Cancer Immunotherapy (ECI®) later this year.
  • This expansion of capacity in anticipation of demand reinforces the company's commitment to improving cancer treatment outcomes in veterinary patients through the advancement of innovative therapies.
  • In addition to accommodating increased demand for ECI®, the new manufacturing facility will enable the company to continue development work on its pipeline of innovation.
  • The company recently announced it has launched pursuit of a $10 million Series A capital raise to support manufacturing expansion, commercial launch of ECI®, and continued development on the company's product pipeline.

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Retrieved on: 
Tuesday, April 30, 2024
Climate change, Food, Stroke, World Health Organization, Risk, Climate, Health, Infection, City, Diabetes, Research, Growth, Obesity, Disease, Poverty, Bill, Cardiovascular disease, Notifiable disease, Novo Nordisk Foundation, Tuberculosis, Knowledge, Agriculture

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.

Key Points: 
  • The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
  • The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them.
  • "At the Novo Nordisk Foundation, we work to improve the health of people and the planet," says Mads Krogsgaard Thomsen, CEO of the Foundation.
  • "These are closely connected but, all too often, scientific research occurs in silos and the outcomes don't meet the needs of a world facing complex challenges.

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Retrieved on: 
Tuesday, April 30, 2024
Climate change, Food, Stroke, World Health Organization, Risk, Climate, Health, Infection, City, Diabetes, Research, Growth, Obesity, Disease, Poverty, Bill, Cardiovascular disease, Notifiable disease, Novo Nordisk Foundation, Tuberculosis, Knowledge, Agriculture

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.

Key Points: 
  • The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
  • The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them.
  • "At the Novo Nordisk Foundation, we work to improve the health of people and the planet," says Mads Krogsgaard Thomsen, CEO of the Foundation.
  • "These are closely connected but, all too often, scientific research occurs in silos and the outcomes don't meet the needs of a world facing complex challenges.

SHATTERPROOF AND ANTHEM BLUE CROSS FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER IN CALIFORNIA

Retrieved on: 
Monday, April 29, 2024
Mortality, Patient, CME, Learning, Risk, CDC, Suds, SASI, Elevance Health, Health care, Partnership, Substance use disorder, Research, Curriculum, Addiction medicine, Mental health, Society, Physician, Conditional sentence, ASAM, Osteopathy, Organization, CE, Disease, Nursing

BAKERSFIELD, Calif., April 29, 2024 /PRNewswire/ -- A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof Addiction Stigma Index (SASI) found that healthcare professionals hold similar stigmatizing beliefs toward someone with a SUD. Specifically, 65% of healthcare professionals falsely believe that a SUD isn't a chronic disease.

Key Points: 
  • The Shatterproof Addiction Stigma Index (SASI) found that healthcare professionals hold similar stigmatizing beliefs toward someone with a SUD.
  • To address addiction stigma among healthcare professionals, Shatterproof, a leading national nonprofit organization dedicated to reversing the addiction health crisis, is teaming up with Anthem Blue Cross Foundation to bring additional learning to the healthcare community, reduce stigma of individuals with substance use disorders (SUDs) and improve quality of care.
  • The funding for the partnership is through the Anthem Blue Cross Foundation, a philanthropic arm of the Elevance Health Foundation .
  • "Anthem Blue Cross recognizes the long-standing racial and health inequities in our healthcare system and our society as a whole," said Les Ybarra, president, Anthem Blue Cross Medi-Cal Health Plan.

5 Ways Heart Health Care Can Improve

Retrieved on: 
Monday, April 29, 2024
The Harris Poll, Education, Brain, Public, Cancer, Food, Disorder, FAHA, Stroke, Pneumonia, Housing, Prevalence, CVD, Risk, Health, Infection, Heart, Radiology, Death, Research, Artificial intelligence, Life, Stanford School, Disease, Moyamoya disease, Physician, Cardiovascular disease, Diphtheria, Roflumilast, Tuberculosis, Overalls, American Heart Association, Heart failure, Pharmaceutical industry

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."

Key Points: 
  • "Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."
  • Non-traditional approaches to health care are needed to address the social and structural determinants of health by moving evidence-based approaches rapidly into communities to address food insecurity, transportation problems, education, housing, access to care, chronic psychosocial stress and other social needs.
  • The interconnectedness of organ systems, mechanisms of disease and stages of life are critical to understanding the role cardiovascular health plays in overall health.
  • As we apply these same clinical and epidemiological methods to the someday hopeful eradication of heart disease and stroke, the American Heart Association is making great progress.

SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND SUBSTANCE USE DISORDER

Retrieved on: 
Monday, April 29, 2024
Mortality, Patient, Blue Shield, Learning, Risk, Suds, SASI, Health, Elevance Health, Health care, Partnership, Substance use disorder, Curriculum, Mental health, Physician, Conditional sentence, Osteopathy, Organization, Disease, Nursing

BRONX, N.Y., April 29, 2024 /PRNewswire/ -- A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof Addiction Stigma Index (SASI) found that healthcare professionals hold stigmatizing beliefs toward someone with a SUD. Specifically, 65% of healthcare professionals falsely believe that a SUD isn't a chronic disease.

Key Points: 
  • To address addiction stigma among healthcare professionals, Shatterproof, a leading national nonprofit organization dedicated to reversing the addiction health crisis, is teaming up with Anthem Blue Cross and Blue Shield Foundation to bring additional learning to the healthcare community, reduce stigma of individuals with substance use disorders (SUDs) and improve quality of care.
  • In partnership with Anthem Blue Cross and Blue Shield Foundation, Shatterproof will better the lives of people in recovery, people who use drugs, and people seeking treatment for substance use disorders."
  • "At Anthem Blue Cross and Blue Shield, we recognize the impact that long standing health and social inequities have had on communities of color," said Dr. Mark Levy, President and CEO, Anthem Blue Cross and Blue Shield, HP.
  • The funding for the partnership is through the Anthem Blue Cross and Blue Shield Foundation, a philanthropic arm of the Elevance Health Foundation .